'

Supriya Lifescience hosted a conference call on Jan 27, 2025. During the call, the company was represented by Dr. Satish Wagh, Executive Chairman & WTD; Dr. Saloni Wagh, Managing Director; and Mr. Krishna Raghunathan, Chief Financial Officer.

Key takeaways of the call

The company reported revenue growth of 33% YoY supported by efficient execution across therapeutic segments.

Focus on niche and high value products has led to significant improvement in EBITDA margin. Going forward, management expects strong margin to sustain.

In Q3 FY25, Asia contributed 31% to total revenue, Europe 40%, LAC 21%, North America 3% and others 5%.

During 9M FY25, Asia contributed 32% to total revenue, Europe 43%, LAC 17%, North America 4% and others 4%.

In Q3 FY25, in terms of therapy wise contribution...

• 

  (05-Feb-2025)

  Castrol India

  Expects EBITDA margin of 22%-25% for CY25
• 

  (10-Feb-2023)

  Deepak Nitrite

  Plans capex of about Rs 1500 crore for FY23 and FY24
• 

  (09-Feb-2023)

  Mayur Uniquoters

  Targets revenue of Rs 1000 crore in FY24
• 

  (31-Jan-2023)

  Tega industries

  Capex plan is US$ 30-32 million for next three years